Ovid Therapeutics (OVID) Operating Leases (2022 - 2026)

Ovid Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• Quarterly Operating Leases fell 11.16% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 11.16% YoY) and the FY2025 annual result came in at $12.0 million, down 10.68% from the prior year.
• Operating Leases was $11.6 million for Q1 2026 at Ovid Therapeutics, down from $12.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $16.2 million in Q3 2022 and bottomed at $11.6 million in Q1 2026.
• A 5-year average of $14.3 million and a median of $14.4 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases retreated 1.09% — and 2026, when it dropped 11.16%.
• Ovid Therapeutics' Operating Leases stood at $16.0 million in 2022, then retreated by 7.78% to $14.8 million in 2023, then dropped by 9.06% to $13.4 million in 2024, then fell by 10.68% to $12.0 million in 2025, then declined by 3.13% to $11.6 million in 2026.
• Business Quant data shows OVID's Operating Leases at $11.6 million in Q1 2026, $12.0 million in Q4 2025, and $12.4 million in Q3 2025.